Bonn, Univ., Diss., 2005. / Computerdatei im Fernzugriff.

Universiẗat, Diss., 2005--Bonn.

No description available.

Reactivation of latent infection is the major cause of tuberculosis (TB). Cholesterol is a critical carbon source during latent infection. Catabolism of cholesterol contributes to the pool of propionyl-CoA, a precursor that is incorporated into cell-wall lipids. Arylamine N-acetyltransferase (NAT) is encoded within a gene cluster that is involved in the sterol-ring degradation and is essential for intracellular survival. NAT from M. tuberculosis (TBNAT) can utilise propionyl-CoA and therefore was proposed as a target for TB-drug development. Deleting the nat gene or inhibiting the NAT enzyme prevents intracellular survival and results in depletion of cell-wall lipids. NAT inhibitors, including the piperidinol class, were identified by high-throughput screening. The insolubility of recombinant TBNAT has been a major limitation in pursuing it as a drug target. Subcloning tbnat into a pVLT31 vector resulted in a yield of 6-16 mg/litre-bacterial-culture of pure-soluble recombinant TBNAT. The increased yield allowed for extensive screening for crystallisation conditions. However, since a structure was not obtained, the model NAT from M. marinum (MMNAT) was employed to further understand NAT as a target. Screening against a panel of Acyl-CoA cofactors showed that MMNAT can also utilise propionyl-CoA. The MMNAT structure in complex with the high affinity substrate hydralazine was determined (2.1 Å) and the architecture of the arylamine pocket was delineated. A novel mechanism for the acetylation reaction of hydralazine has emerged. It is proposed that the acetyl group is transferred from acetyl-CoA to the heterocyclic aromatic nitrogen of hydralazine, which explains the immediate cyclisation of the acetylated metabolite into an N-methyltriazolophthalazine. By employing mass spectroscopy, enzyme assays, computational docking and structural studies, a covalent mechanism of inhibition by the piperidinol class was established, and the inhibitor-binding pocket was identified. Inhibitors with new scaffolds were identified using the in silico 3D-shape screening and thermal shift assay.

Thesis (PhD (Molecular Biology and Human Genetics))--University of Stellenbosch, 2005. / 157 leaves single sided printed, preliminary pages i-xvii and numbered pages 1-141. Includes bibliography, and abbreviations and a list of figures. / ENGLISH ABSTRACT: A gene coding for Arylaminie N-acetyltransferase (NAT) has been found in Mycobacterium tuberculosis, the casual agent of tuberculosis (TB). N-acetyltransferase acetylates and inactivates isoniazid (INH), which is a front line drug used in TB therapy. A guanine to adenine SNP at basepair 619 (G619A) has previously been identified in this gene, which results in a glycine to arginine change at amino acid 207 (G207R) (Upton et al. 2001). In this study the nat gene was further characterised. The frequency of the G619A SNP was analysed in 37 M tuberculosis strain families found in the Western Cape Province of South Africa, and it was found that the G619A SNP is conserved in two strain families (strain family 3 and strain family 28). Further sequence analysis identified a new thymine to cytosine SNP at base-pair 529 (T529C) resulting in a tyrosine to histidine change at amino acid 177 (Yl77H). This SNP was found only in isolates from strain family 3. These results imply that these SNPs may be used in epidemiology studies to classify isolates into these strain families. Using Real Time PCR, the expression of nat in M bovis BCG and M tuberculosis (reference strain H37Rv) was determined over a 7 and 28 day growth cycle, respectively. Using 16S rRNA as an endogenous control, the nat gene was shown to be expressed early during the growth curve and reach its maximum expression level at approximately mid-log phase. The expression of nat was induced in drug susceptible M tuberculosis isolates (reference strain H37Rv and isolate 1430 containing both SNPs) exposed to INH at a concentration of O.Oll-lg/ml, but minimal change in expression was observed in resistant isolates (isolate 816) exposed to INH at the same concentration. Mycobacterium bovis BCG cultures exposed to INH, at a final concentration of 0.28I-lg/ml, showed an increase in protein production. The increase of nat mRNA and NAT protein in M tuberculosis and M bovis BCG, respectively, implies that INH affects the expression of NAT. The NAT protein was localised to all fractions of the cell in Mycobacterium smegmatis, M bovis BCG and M tuberculosis, using the Western blot technique. However, protein fractions from the cell envelope region showed a protein (detected with specific NAT antibodies) that ran at a higher molecular weight (MW). This implies that the cytosolic hydrophilic NAT undergoes some type of post-translational process that may make it hydrophobic, and enable it to pass into the cell envelope region. These results show for the first time how nat is expressed during the entire growth cycle of M tuberculosis and M. bovis BeG. It was shown that nat is expressed early during the growth cycle of the bacterium reaching maximum expression levels at mid-log phase. These results are in concordance with those obtained using M. smegmatis nat mutants, which taken together, show that early expression of nat is important for early growth and development of mycobacteria. The results in this study also showed that NAT appeared to be translocated into the cell envelope of the bacterium, implying that NAT may be involved in one of the pathways needed for complete formation of the cell envelope. These results suggest that NAT may be an important target for drug development, as inhibitors of NAT could result in hindered growth and hence spread of the bacterium within its host. Inhibitors may also result in the incomplete development of the cell wall, enabling the host to combat the disease using its own immune system.

Flavonoids are natural compounds commonly ingested in herbs and vegetables. They are believed to have a positive impact on human organism, in particular by their antioxidant, hepatoprotective and anti-cancer effects. In these days, it is possible to consume high concentrations of these compounds in form of dietary supplements. However it is not clear, whether flavonoids in such unnaturally high concentrations are still beneficial or rather harmful. It has already been proven, that flavonoids can influence the activity of biotransformation enzymes and interfere e.g. with the process of carcinogenesis and drug metabolism. For that reason it is important to investigate the impact of an increased intake of flavonoids. The aim of this thesis was to investigate the influence of dihydromyricetin (a potential drug to cure alcohol use disorder) and its structurally similar flavonoid myricetin on the activity of enzymes, cytochrome P450 2E1 (CYP2E1) and N­acetyltransferases 1 and 2 (NAT1/2). The research included the determination of the impact of a premedication by these flavonoids on the expression and activity of CYP2E1 and NAT1/2. The inhibition capacity of myricetin and dihydromyricetin towards the activity of CYP2E1 and NAT1/2 was also investigated. After the flavonoid premedication of rats the...

Fatty acid amides are an emerging family of bioactive lipids that consists of N-acylethanolamines, N-acylarylalkylamides, N-acylglycines, N-acyl amino acids, N-monoacylpolyamides, and primary fatty acid amides. Short chain fatty acid amides are products of inactivated biogenic amines such as dopamine, histamine, octopamine, and serotonin, whereas long chain fatty acid amides have been implicated in a number of physiological process such as the perception and inhibition of chronic pain through binding to their specific receptors. The most famous; therefore, the most studied long chain fatty acid amide is anandamide or also known as N-arachidonylethanolamine. The biosynthesis of anandamide is well defined; however, other long-chain fatty acid amides, such as the N-acyldopamines, N-acylserotonins, N-acylglycines, N-acyl amino acids, and primary fatty acid amides have remained elusive to date. Understanding the complete biosynthetic pathway for these cell signaling lipids, may yield new exciting molecular targets for human health and disease. Discovery of the long-chain fatty acid amide biosynthetic enzymes has proven to be challenging due to the low biologic abundance of the respective metabolites found in organisms, the interconnection of the pathways, and expense of using mammalian cells and/or organisms. This led to the transition of studying these metabolites and their respective biosynthetic enzymes in Drosophila melanogaster. D. melanogaster is an ideal system to study fatty acid amide biosynthesis because the respective metabolites have been identified, the cost of maintaining the organism is relatively low, and genetic manipulation (RNAi) is universally available. This dissertation is dedicated to defining enzymes involved in D. melanogaster N-acylarylalkyamide biosynthesis. The biologically relevant long-chain N-acylarylalkylamides are comprised of long-chain N-acyldopamines and N-acylserotonins. Very little is known for how these potent cell signaling lipids are biosynthesized in the cell. One possible route is the N -acylation of the respective biogenic amine by an N-acyltransferase enzyme. An enzyme known to catalyze this chemistry is arylalkylamine N-acetyltransferase (AANAT), which catalyzes the formation of N-acetylarylalkylamides from acetyl CoA and the corresponding arylalkylamide. The N-acetylation of biogenic amines is a critical step in Drosophila melanogaster for the inactivation of amine neurotransmitters, sclerotization of the cuticle, and to serve as the penultimate intermediate in the biosynthesis of melatonin. Two AANAT(L) enzymes has been previously evaluated in D. melanogaster and six other putative AANATL enzymes have identified in the fly genome. One AANAT is expressed as two biologically relevant isoforms, AANAT variant A (AANATA) and AANAT variant B (AANATB), where AANATA differs from AANATB by the truncation of 35 amino acids on the N-terminus. The other AANATL enzyme to be previously studied is AANATL2, which was found to catalyze the formation of N-acetyltryptamine from acetyl CoA and tryptamine. Herein, we expressed six AANAT(L) enzymes (AANATA and AANATB, AANATL2, AANATL3, AANATL7, and AANATL8) and sought to define the acyl-CoA and amine substrates for each enzyme. To accomplish this, we developed an activity based screening assay to define acyl-CoA and amine substrates for AANATL2, AANATL3, AANATL7, and AANATL8. Following this work, we defined the acyl-CoA and amine substrate specificity for AANATA, AANATL2, AANATL3, and AANATL7. We have identified acetyl CoA and arylalkylamines as substrates for AANATA, AANATL2, and AANATL3; whereas AANATL7 acetylates histamine and arylalkylamines. AANATL2 was additionally shown to catalyze the formation of long-chain N-acyldopamines and N-acylserotonins. Following these important set of results, we solved the kinetic mechanism for AANATA, AANATL2, and AANATL7 in which these enzymes were shown to catalyze the formation of N-acylarylalkylamides by an ordered sequential mechanism where the acyl-CoA substrate binds first followed by the corresponding amine substrate. Finally, we evaluated the function of structural amino acids on regulating catalysis, structural features of substrates that effect binding and/or catalysis, and generated data leading to a proposed chemical mechanism by means of pH-activity profiles and site-directed mutagenesis of prospective catalytic residues.

Prostate cancer (PCa) is one of the most prevelant cancers in males in many countries, increasing in frequency with age. PCa incidence and mortality rates are not evenly distributed worldwide. Family history is an established risk factor for prostate cancer and families demonstrating autosomal dominant or X-linked transmission of susceptibility have been observed. Although an increasing number of candidate genes or hereditary prostate cancer susceptibility have been identified, only 5 to 10 percent of prostate cancer cases in the population may arise from major susceptibility genes. A few risk factors for PCa development are advanced age, an intact androgen metabolism, ethnicity, and genetic background. Other genetic factors, in combination with possible environmental risk factors for prostate cancer, may have greater public health importance. Genetic polymorphisms that may be associated with prostate cancer risk are much more common in the population than are high-penetrance cancer susceptibility genes. In this study, the effect of N-acetyltransferase 2 (NAT2) and Glutathione S-transferases (GSTM1 and GSTT1) were investigated, since polymorphism in these genes may alter their enzymatic activity and, therefore, their capacity to biotransform xenobiotic compounds. In order to evaluate the potential association between NAT2 , GSTM1 and GSTT1 genotypes and prostate cancer risk, a hospital based case control study was carried out in a Turkish population consisting of 30 histologically confirmed incident prostate cancer cases and 67 control subjects with no present or previous history of cancer. The GSTM1 and GSTT1 genotypes showed no significant differences between case and control groups, with respect to their frequencies and it was observed that GSTM1 null genotype was more common in cases with a 60% frequency. Even though the frequency of slow NAT2 acetylator genotype was 80% in cases and 50,7% in controls NAT2 rapid acetylator showed no association with prostate cancer statistically. These results suggested that GSTM1 null genotype is a susceptibility factor for prostate cancer, particularly in the presence of NAT2 slow acetylator genotype with no significance. Further studies with a larger size are required to confirm the presence and significance of this relationship.

Gegenstand der Untersuchung: Vorliegende Arbeit stellt eine molekularbiologische Studie dar, die der Frage nachging, ob der Genotyp für die NAT2 eine Rolle bei der Pathogenese des Mammakarzinoms spielt. Das Mammakarzinom hat eine erbliche Komponente. Neben hoch-penetranten genetischen Mutationen des BRCA1- und BRCA2-Gens stehen polymorphe Enzyme des Fremdstoffwechsels im Verdacht, Präkanzerogene zu aktivieren und somit das Karzinomrisiko zu erhöhen. Die NAT2 detoxifiziert aromatische Amine, wie sie z. B. im Zigarettenrauch enthalten sind und weist eine ausgesprochene bimodale Aktivitätsverteilung auf. Nach systematischer Aufklärung des genetischen Polymorphismus der NAT2 ist eine Vorhersage des Phänotyps mit hoher Sicherheit möglich. Design: Es wurde eine prospektive Fall-Kontroll-Studie an 248 Patientinnen mit Mammakarzinom und 248 Kontrollen (Patientinnen mit anderen, nicht malignen Erkrankungen und Gesunde) durchgeführt. Zusätzlich wurde eine Blutprobe entnommen, aus der DNA isoliert wurde. Damit wurden folgende Mutationen des NAT2-Gens bestimmt: G191A, C282T, T341C, C481T, G590A, A803G, G857A. Anhand dieser Mutationen erfolgte die Zuordnung zu Haplotypen. Da bekannt ist, welche mittlere Aktivität der NAT2 bei den einzelnen Genotypen zu erwarten ist, konnte mit dieser Information eine Vorhersage der Aktivität als "schnelle" und "langsame" Acetylierer vorgenommen werden. Methode: Die Genotypisierung erfolgte durch Amplifikation des NAT2 -Gens mit verschiedenen Primern in der PCR, anschließendem Verdau mit Restriktionsenzymen und Charakterisierung der Fragmente mittels Gelelektrophorese. Statistik: Mit der Berechnung von "Odds ratios" und multivariaten logistischen Regressionsanalysen zur Berücksichtigung möglicher Einflussfaktoren wurde der Zusammenhang zwischen NAT2-Genotyp bzw. daraus vorhergesagtem Phänotyp und Mammakarzinom überprüft. Ergebnisse: Es wurden acht verschiedene NAT2-Haplotypen nachgewiesen. 2 Haplotypen (*4 und *12A) kodieren für einen schnellen Acetylierer-Typ, 6 Haplotypen (5A, 5B, 5C, 6A, 7B und 14*B) für den langsamen Acetylierer-Typ. 55,6% der MC-Patientinnen und 58% der Kontrollpersonen Genotypen wiesen den langsamen Acetyliererstatus auf. Dies entspricht in etwa der von anderen Untersuchern beschriebenen Häufigkeit bei Kaukasiern. Es fand sich keine Überrepräsentierung bestimmter Genotypen oder Haplotypen in der Gesamtgruppe der Patientinnen mit Mammakarzinom im Vergleich zur Kontrollgruppe. Die Odds ratio betrug 1,12 (CI: 0,03 - 1,60). In einer Subgruppenanalyse fanden sich keine signifikante Unterschiede in bezug auf das mittlere Alter, das Ausmaß des Zigarettenkonsums und auch von Blutgruppenmerkmalen. Innerhalb des Patientenkollektivs wurde die Verteilung von schnellen und langsamen Acetylierern stratifiziert nach Menopausenstatus, Menstruationsdauer, TNM-Klassifikation und Grading. Bei den Patientinnen mit invasiv-lobulärer Tumorhistologie waren die schnellen Acetylierer in der Auswertung signifikant häufiger als bei invasiv-duktalem Mammakarzinom. Ein weiterer signifikanter Unterschied wird bezüglich des Hormonrezeptorstatus berichtet: Schnelle Acetylierer waren bei Patientinnen mit positivem Hormonrezeptorstatus deutlich häufiger als bei solchen mit negativem Rezeptorstatus. Bezüglich der Tumorhistologie fiel auf, dass die 33 Patientinnen mit einem invasiv-lobulären Mammakarzinom signifikant häufiger schnelle Acetylierer waren. Langsame Acetylierer wiesen dagegen häufiger einen negativen Östrogenrezeptorstatus auf. Schlussfolgerung: Dem Polymorphismus des NAT2-Genotyps als unabhängigem Risikofaktor bei der Entstehung des Mammakarzinoms kommt keine mit den bekannten Risikofaktoren vergleichbare Bedeutung zu. Die Befunde in bezug auf die Tumorhistologie und auf den Hormonrezeptorstatus weisen möglicherweise auf Besonderheiten im Pathomechanismus bei der Entstehung des Mammakarzinoms hin, der derzeit unklar ist. Sie bedürfen weiterer Abklärung. / Genetically polymorphic xenobiotic metabolizing enzymes such as the polymorphic arylamine N-acetyltransferase (NAT2) are supposed to be a host factor for cancer susceptibility. A case-control study of a total of 248 patients with breast cancer and a matched reference group of 248 unrelated subjects without cancer was performed to explore the association between NAT2 genetic polymorphism and individual susceptibility to breast cancer. A structured questionnaire was used to collect relevant information regarding all known or suspected risk factors of breast cancer. Methods: The NAT2 genotype was determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The NAT2-genotype was characterized at nucleotide positions 191, 282, 341, 481, 590, 803, and 857. For evaluation of nucleotide 341, a 3’-mismatch primer was used. Homozygous wild type genotypes NAT2*4/*4 were confirmed by DNA sequencing. Results: Genotypes for rapid acetylation amounted to 44.4% among breast cancer and 41.5% among reference patients. There was no over-representation of specific NAT2-genotypes in the total of breast cancer patients compared with the reference group (odds ratio 1.12, 95%; confidence limits 0.03-1.60). Neither NAT2-status nor smoking status was independently associated with breast cancer risk. Logistic regression analysis, considering confounders such as age, body mass index (BMI), and smoking status (PJ) showed that the NAT2 rapid acetylator genotype was not associated with an increased cancer risk (odds ratio 1.05; 95%-CI: 0.67-1.67; P=0.82). Discrimination into homozygous and heterozygous carriers of allele NAT2*4 did not show any over-representation of NAT2*4/*4 genotypes among breast cancer patients (odds ratio 1.31; 95% confidence limits 0.59-2.91; p=0.50). Hence carriers of the NAT2*4/*4 genotypes, with its especially high acetylation capacity are not at significantly increased risk to breast cancer. Further stratification to different risk factors revealed a non-significant elevation in risk of breast cancer among patients with increasing cigarette smoking who represented the NAT2 rapid acetylator genotype, but lack of association to age, blood groups, menopause, period of menstruation, TNM-classification, tumor grading, and histology. However, evaluation of the role of estrogen receptor status and NAT2 showed that there was a significant association between positive receptor status and NAT2 rapid acetylator genotype (odds ratio 2.07; 95%-CI: 1.32-5.27; P=0.005). Interestingly, in patients with infiltrating lobular breast cancer (n = 33), NAT2 rapid acetylator genotypes were more frequent compared with other tumor subtypes (odds ratio 2.59; 95%-CI: 1.20-5.60; P=0.014). Logistic regression analysis, considering estrogen receptor status, and age showed that the rapid acetylator genotypes were associated with an increased cancer risk (odds ratio 2.4; 95%-CI: 1.04-5.61; P=0.04). Our findings suggest that NAT2-polymorphism is not an independent susceptibility factor for breast cancer. In particular the NAT2 slow acetylator genotype was not associated with an increased breast cancer risk. Striking results point out to a likely association between NAT2 rapid acetylator genotype and tumor histology especially infiltrating lobular breast cancer and positive hormone receptor status These findings refer to special features of pathogenesis in breast cancer requiring more and detailed clarification.

This thesis describes the design, synthesis, analysis, mechanistic evaluation and optimisation of small molecule probes for the specific detection of proteins, focusing on the target protein human arylamine <i>N</i>-acetyltransferase type 1 (HUMAN(NAT1)) and its murine homologue, mouse arylamine <i>N</i>-acetyltransferase type 2 (MOUSE(NAT2)). The HUMAN(NAT1) gene is reported to be one of the most highly overexpressed genes in estrogen-receptor-positive (ER+) breast tumours, leading to its potential use as both a novel diagnostic biomarker and a novel therapeutic target for this disease. <strong>Chapter 1</strong> reviews the literature on optical methods for the specific detection of a protein target, exploring strategies both based on biosensors and on chemical probes, before introducing the arylamine <i>N</i>-acetyltransferases as a family of enzymes. In <strong>Chapter 2</strong>, a family of naphthoquinone inhibitors of HUMAN(NAT1) are introduced, which undergo a colour change from red to blue upon binding specifically to the enzyme. The mechanism of this colour change, a proton transfer-mediated process, is discussed via the synthesis, pharmacological and colorimetric evaluation of close analogues of the hit compound lacking a key acidic sulfonamide-N<i>H</i> proton. During these studies, it was found that direct <i>O</i>-methylation of a sulfonamide is possible under certain conditions; such a reaction has not previously been reported. Furthermore, upon heating in polar solvents the <i>O</i>-methylated sulfonamide was observed to undergo rearrangement, and the mechanism of this process is investigated via NMR and kinetic studies. In <strong>Chapter 3</strong>, the design, synthesis and evaluation of HUMAN(NAT1) inhibitors with improved pharmacological and colorimetric profiles over the initial hit are described. From this optimisation, structure-activity relationships and an in silico model of interactions between the inhibitors and enzyme are evaluated. Testing of these compounds in cellular environments, however, exposes some limitations of this approach, notably the lack of sensitivity of the probes when dosed at low concentrations in cellular samples. In order to overcome this limitation, in <strong>Chapter 4</strong> fluorescent analogues of the hit compound are designed and synthesised. Initial compounds developed in this series possess promising properties, but each compound generated suffers from either a low fluorescent intensity, lack of a <i>p</i>H-dependent switch in fluorescence or a low fluorescence excitation wavelength, which overlaps with those of tryptophan or tyrosine residues in proteins. Insights into the mechanism of molecular fluorescence and application of some simple quantum mechanical principles, however, lead to the design of a species which possesses all the required properties. The fluorescent emission intensity of this probe correlates linearly with [MOUSE(NAT2)] in E. coli cell extracts, and can quantify as little as 0.64% MOUSE(NAT2) in the samples; furthermore, the probe is capable of unambiguously detecting HUMAN(NAT1) within a cell extract from the ER+ breast cancer cell line ZR-75-1; future work on this probe may therefore enable its clinical use in improved early diagnosis of breast tumours. This study also represents, to the best of our knowledge, the first ever example of a small molecule, non-covalent probe capable of quantifying the concentration of a target protein in cellular extracts. In <strong>Chapter 5</strong>, the series of naphthoquinone probes is further optimised in order to study the roles of HUMAN(NAT1) in a cellular environment. Firstly, structure-activity relationships are utilised to design inhibitors with improved physical properties such as aqueous solubility and cell membrane permeability, in order to test the effect of HUMAN(NAT1) inhibitors in tumour cell models, which could have implications for the future use of a HUMAN(NAT1) inhibitor as a therapeutic agent in oncology. Secondly, the effect of the cofactor folic acid on the function and activity of HUMAN(NAT1) is explored. Finally, in <strong>Chapter 6</strong>, the conclusions of this study are outlined and a hypothesis as to how the concepts developed in this thesis might be applied to alternative, more ubiquitous biological targets is discussed, paving the way for future investigations.